BDTX Black Diamond Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BDTX

Price (delayed)

$2.18

Market cap

$112.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.13

Enterprise value

$76.77M

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond ...

Highlights
The company's equity has surged by 63% QoQ
The quick ratio has grown by 47% from the previous quarter and by 40% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.blackdiamondtherapeutics.com
Peers: OMGA

Key stats

What are the main financial stats of BDTX
Market
Shares outstanding
51.64M
Market cap
$112.56M
Enterprise value
$76.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$84.11M
EBITDA
-$83.64M
Free cash flow
-$74.63M
Per share
EPS
-$2.13
Free cash flow per share
-$1.46
Book value per share
$2.6
Revenue per share
$0
TBVPS
$3.38
Balance sheet
Total assets
$172.38M
Total liabilities
$38.07M
Debt
$23M
Equity
$134.32M
Working capital
$131.98M
Liquidity
Debt to equity
0.17
Current ratio
9.76
Quick ratio
9.63
Net debt/EBITDA
0.43
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-57.6%
Return on equity
-78.2%
Return on invested capital
-75.4%
Return on capital employed
-53.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
-2.24%
1 week
-6.84%
1 month
23.16%
1 year
5.31%
YTD
21.11%
QTD
-24.04%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.46M
Net income
-$84.11M
Gross margin
N/A
Net margin
N/A
The net income has grown by 12% YoY
BDTX's operating income is up by 10% YoY but it is down by 2.2% QoQ

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
0.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has increased by 19% YoY and by 7% QoQ
The company's equity has surged by 63% QoQ
The P/B is 28% lower than the last 4 quarters average of 1.2

Efficiency

How efficient is Black Diamond Therapeutics business performance
Black Diamond Therapeutics's ROE has decreased by 33% YoY
The ROA fell by 27% YoY and by 3% QoQ
BDTX's return on invested capital is down by 25% year-on-year and by 3.6% since the previous quarter

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
The quick ratio has grown by 47% from the previous quarter and by 40% YoY
BDTX's current ratio is up by 46% since the previous quarter and by 37% year-on-year
The debt is 83% smaller than the equity
The company's equity has surged by 63% QoQ
Black Diamond Therapeutics's debt to equity has decreased by 41% QoQ and by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.